- Home
- GTBP vs PBM Comparison
GTBP vs PBM Comparison
Compare GTBP & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- PBM
- Stock Information
- Founded
- GTBP 1965
- PBM 1994
- Country
- GTBP United States
- PBM Canada
- Employees
- GTBP N/A
- PBM N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- PBM
- Sector
- GTBP Health Care
- PBM
- Exchange
- GTBP Nasdaq
- PBM NYSE
- Market Cap
- GTBP 6.8M
- PBM 7.5M
- IPO Year
- GTBP N/A
- PBM N/A
- Fundamental
- Price
- GTBP $2.25
- PBM $1.39
- Analyst Decision
- GTBP Strong Buy
- PBM
- Analyst Count
- GTBP 1
- PBM 0
- Target Price
- GTBP $11.00
- PBM N/A
- AVG Volume (30 Days)
- GTBP 244.8K
- PBM 505.8K
- Earning Date
- GTBP 03-25-2025
- PBM 02-02-2025
- Dividend Yield
- GTBP N/A
- PBM N/A
- EPS Growth
- GTBP N/A
- PBM N/A
- EPS
- GTBP N/A
- PBM N/A
- Revenue
- GTBP N/A
- PBM N/A
- Revenue This Year
- GTBP N/A
- PBM N/A
- Revenue Next Year
- GTBP N/A
- PBM N/A
- P/E Ratio
- GTBP N/A
- PBM N/A
- Revenue Growth
- GTBP N/A
- PBM N/A
- 52 Week Low
- GTBP $1.72
- PBM $1.21
- 52 Week High
- GTBP $10.66
- PBM $323.25
- Technical
- Relative Strength Index (RSI)
- GTBP 44.16
- PBM 37.93
- Support Level
- GTBP $2.01
- PBM $1.21
- Resistance Level
- GTBP $2.27
- PBM $2.04
- Average True Range (ATR)
- GTBP 0.22
- PBM 0.25
- MACD
- GTBP -0.01
- PBM 0.04
- Stochastic Oscillator
- GTBP 38.71
- PBM 25.77
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.